A 51-year-old man died last month after receiving an experimental treatment from Sarepta, the third death this year tied to ...

Bank of America downgraded Sarepta Therapeutics (NASDAQ:SRPT) to Underperform from Neutral on Wednesday, becoming the latest ...

The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...

The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb-girdle ...

Sarepta rebuffed a call from the Food and Drug Administration to halt all shipments of its gene therapy for Duchenne muscular ...

Most investors don’t see the drugmaker’s executive management as credible, following the failure to disclose a patient death, ...

Second patient death from liver failure after Sarepta's Elevidys gene therapy triggers FDA investigation. Stock crashes 41% ...

The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...

Sarepta Therapeutics, Inc. faces setbacks with Elevidys, safety issues, and workforce cuts, raising concerns about its ...

Morgan Stanley downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Overweight to Equalweight on Monday, slashing its price target to $40.00 from $113.00 following safety concerns.The stock, which ...

Morgan Stanley (NYSE:MS) downgraded Sarepta Therapeutics (NASDAQ:SRPT) from Overweight to Equalweight on Monday, slashing its price target to $40.00 from $113.00 following safety concerns. The stock, ...

Morgan Stanley (NYSE: MS) downgraded Sarepta Therapeutics (NASDAQ: SRPT) from Overweight to Equalweight on Monday, slashing its price target to $40.00 from $113.00 following safety concerns.The stock, ...